Purpose: The determinants of long-term survival in glioblastoma have remained largely obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common in World Health Organization (WHO) grades II and III gliomas, but rare in primary glioblastomas, and associated with longer survival.
Introduction
According to the World Health Organization (WHO) classification of brain tumors, glioblastomas (WHO grade IV) are defined as malignant astrocytic tumors with necrosis or microvascular proliferation or both (1) . They most commonly occur de novo and are then referred to as primary glioblastomas. Less frequently, they develop by progression from lower grade gliomas and are then referred to as secondary glioblastomas. The overall prognosis of glioblastoma has remained poor. In a prospective study of 301 primary glioblastoma patients enrolled in the German Glioma Network (GGN), we observed a median overall survival (OS) of 12.5 months (2). However, a small fraction of patients survive for more than 36 months. We have previously arbitrarily defined these patients as long-term survivors (LTS) and clinically characterized these patients as being younger at diagnosis and having a good initial performance score. Molecularly, their tumors showed an increased rate of MGMT promoter hypermethylation (74% vs. 30-35% in the general glioblastoma population; ref. 3) .
More recently, mutations in the gene encoding cytosolic NADPþ-dependent isocitrate dehydrogenase 1 (IDH1) were identified in a minority of glioblastoma patients. They are more common in younger patients with primary glioblastoma and in patients with secondary glioblastoma and associated with increased OS (4, 5) . In contrast, IDH1 mutations are detected in 60% to 90% of diffusely infiltrating gliomas of WHO grades II and III (6) (7) (8) (9) (10) (11) (12) . IDH1 mutations occur exclusively in codon 132 and around 93% are R132H alterations (7) . Moreover, mutations in the gene encoding the mitochondrial NADPþ-dependent IDH2 were identified in around 3% of WHO grade II and III gliomas and secondary glioblastomas (7, 12) . Thus, the differential distribution of IDH1/2 mutations among gliomas provided strong support for the differentiation of secondary from primary glioblastoma and helped to molecularly dissect primary glioblastoma into distinct molecular subgroups (2, 10) . These considerations led us to reanalyze and expand our original cohort of LTS glioblastoma patients (3) to address the question to what extent IDH1/2 mutations account for the LTS phenotype and to identify characteristic features of the IDH1/2 wild-type LTS phenotype.
Materials and Methods

Patient recruitment and histology
Sixty-nine patients with primary glioblastoma and an OS of >36 months were identified by the 8 clinical centers and 2 associated clinical centers of the GGN (www. gliomnetzwerk.de). To be eligible for this analysis, it was required that the first histologic diagnosis was that of a glioblastoma according to the WHO classification of central nervous system tumors (1) confirmed by central pathology review at the Brain Tumour Reference Center of the German Society of Neuropathology and Neuroanatomy (DGNN). Clinical and part of the molecular data of 36 patients have been published previously, but were updated and complemented for IDH1/2 mutation status for this report (3), data of 9 other patients have been included in another publication of the GGN (2). The study was approved by the local ethics committees at the GGN clinical centers and written informed consent was obtained from each patient. As a reference group, we used a cohort of 257 primary glioblastoma patients published previously, but excluded all patients who survived for more than 36 months (2) .
DNA extraction and analysis for MGMT promoter methylation, 1p/19q codeletion, EGFR amplification, and TP53 mutation DNA was extracted by standard methods either from formalin-fixed paraffin-embedded tumor tissue or from unfixed frozen tumor tissue samples. MGMT promoter methylation analysis was carried out by methylation-specific PCR. EGFR gene dosage was determined by real-time PCR analysis. Losses on 1p and 19q were determined either by multiplex ligation-dependent probe amplification or by loss of heterozygosity analysis of 5 different microsatellite markers on each chromosomal arm. TP53 mutations were determined by single-strand conformation polymorphism analysis followed by direct sequencing. Details of the respective molecular methods have been reported elsewhere (2, 3, 13) .
IDH1 and IDH2 mutation analysis IDH1 codon 132 and IDH2 codon 172 were analyzed by direct sequencing. In case of ambiguous results, the IDH1 or IDH2 sequences were amplified by a different set of primers (6, 7) . In addition, 26 LTS patients that carried neither IDH1 nor IDH2 mutations in the respective codons were tested for IDH1 codon 100 mutations (14) .
Statistical analysis
Fisher's exact test or the x 2 tests were used to compare the frequencies of molecular aberrations and clinical data in the long-term survivor group versus the control group. OS was calculated from the date of first surgery for glioblastoma until the time of death or last follow-up examination. Survival curves were compared using the log-rank test. Progressionfree survival (PFS) was determined from day of first surgery until tumor progression, death, or end of follow-up. Cox regression and multivariate logistic regression analyses were conducted. HR and OR with 95% confidence intervals (95% CI) were determined. All analyses were conducted using IBM SPSS Statistics Version 20.
Results
Patient characteristics
We identified 69 patients with a survival >36 months and a median follow-up of 73 months (LTS-36 cohort). Of these patients, 33 patients were ascertained to have survived for 60 months (LTS-60). These 2 cohorts were compared to a cohort of 257 glioblastoma patients who survived for less than 36 months and had a median follow-up of 23.6 months. Demographic, clinical, and molecular characteristics of these 3 cohorts are summarized in Table 1 . Seventeen of 69 LTS-36 and 15 of 33 LTS-60 patients are alive. LTS-36 patients were younger than control patients (P < 0.001), but there was no enrichment of young patients in the LTS-60 group relative to the entire LTS-36 group of patients. The relative frequency of glioblastomas with oligodendroglial component was increased in the LTS cohorts. Initial KPS was similar among groups. There were fewer temporal tumors in LTS-36 patients (P ¼ 0.185), but this difference was not significant, even if the analysis was
Translational Relevance
Although the prognosis of patients with primary glioblastoma is generally poor, a minority of patients achieve long-term survival beyond 36 months. We here report that the rate of isocitrate dehydrogenase 1/2 (IDH1/2) mutations in such patients is 34% as opposed to 4.3% in controls and thus substantially increased. Molecular marker profiles of IDH1/2-mutant primary glioblastoma correspond to that of secondary glioblastomas which are typically IDH1/2-mutant, too. IDH1/2 wild-type glioblastoma patients with long-term survival exhibit no characteristic marker profile distinguishing them from ordinary IDH1/2 wild-type glioblastoma patients with poor outcome, suggesting that hostderived factors, for example, immune responsiveness, contribute to long-term survival in such patients. restricted to the control cohort versus the LTS-60 cohort. LTS-36 patients had only slightly more often a gross total resection and slightly less often a biopsy than control patients (P ¼ 0.379). Compared with control patients, LTS-36 patients had more often 2 or more further surgical interventions (P < 0.001), were more often re-irradiated (P ¼ 0.066), and received 1 or 2 lines of salvage chemotherapy more often (P < 0.001). First-line treatment after surgery was overall similar except that LTS-60 patients received more often radiotherapy plus chemotherapy than radiotherapy alone relative to the other groups (n.s.). PFS with the first therapeutic intervention was 5-fold as long in LTS-36 patients compared with control patients. Seven patients in the LTS-60 cohort have not suffered progression: 5 are alive, 1 died of renal cell carcinoma, and cause of death is unknown in the other patient.
Molecular markers
The results of molecular analyses are summarized in Table  1 and Fig. 1 . LTS-36 patients had more often MGMT promoter-methylated tumors than the control group (P < 0.001). 1p/19q codeletions were rare and not more common in LTS patients. EGFR amplification was less common in LTS-36 patients (P ¼ 0.037). The relative frequencies of TP53 mutations were similar in LTS-36 and control patients (P ¼ 0.203). IDH1 mutations were much more common in the LTS-36 cohort (32.8%; 22 of 67) than in the control cohort (9 of 248; P < 0.001). Among LTS patients, an IDH1 R132H mutation was identified in 20 patients, an IDH1 R132S mutation in 1 patient and an R132C mutation in 1 patient. In the control group, 9 IDH1 mutations were found, all of the R132H type. One IDH2 mutation was identified in 65 LTS-36 patients and 2 IDH2 mutations in the control cohort. Among the 33 LTS-60 patients, fewer patients had TP53 mutations than in the entire LTS-36 cohort. We observed 13 patients in the LTS-60 cohort that had no salvage therapy, 6
with IDH1/2-mutant tumors and 7 with IDH1/2 wild-type tumors. The tumors of 6 patients with IDH1/2 mutation (median age 39 years) were MGMT promoter methylated and had no EGFR mutation. Six of 7 patients with IDH1/2 wild-type tumors (median age 60 years) had MGMT promoter methylation and 4 of 6 patients had tumors without EGFR mutation.
Prognostic factors for LTS-36
Next we asked which factors influenced the likelihood to become an LTS-36 patient and conducted a multivariate logistic regression analysis. We included age (50 vs. >50), KPS (80 vs. <80), extent of resection (total vs. no total) and 4 genetic alterations (MGMT promoter methylation, IDH1/2 mutation, EGFR amplification, TP53 mutation) as main factors. The most important prognostic factors for surviving for at least 36 months were MGMT status, IDH1/2 status, and age (Table 2) . Table 3 shows a comparison of control patients as well as LTS-36 and LTS-60 patients with versus without IDH1/2-mutant tumors.
IDH1/2-mutant glioblastoma versus IDH1/2-wild-type glioblastoma with LTS LTS patients with IDH1/2-mutant tumors were younger (P ¼ 0.001), had more often frontal as opposed to temporal or parietal tumors (P ¼ 0.013), had more often an oligodendroglial component (P ¼ 0.099), and were treated with radiotherapy alone initially more often (P ¼ 0.169). The molecular profile of IDH1/2-mutant tumors of LTS-36 patients was characterized by a higher rate of MGMT promoter methylation (P ¼ 0.307), 1p/19q codeletions (P ¼ 0.046), and TP53 mutations (P ¼ 0.345), and the absence of EGFR amplification (P ¼ 0.001). Individual profiles are provided in Supplementary Tables S1 and S2 . Among patients with wild-type IDH1/2 status, MGMT promoter methylation provided a HR for death of 0.47 (95% CI, 0.22-1.0; P ¼ 0.053). Only 2 patients had IDH1/2-mutant tumors lacking MGMT promoter methylation. Conversely, wild-type TP53 status conferred a risk reduction both in patients with IDH1/2-mutant (0.28; 95% CI, 0.09-0.82; P ¼ 0.020) and IDH1/2 wild-type (0.59; 95% CI, 0.24-1.45; P ¼ 0.250) tumors. We also assessed survival probability by molecular marker status in glioblastoma patients surviving for at least 36 months (LTS-36 cohort). Figure 2 shows that, among the LTS-36 patients, IDH1/2 status was prognostically irrelevant (P ¼ 0.414) whereas MGMT promoter methylation (P ¼ 0.078), wild-type TP53 status (P ¼ 0.015) and absence of EGFR amplification (P ¼ 0.106), with descending magnitude of effect, were associated with increased survival. Figure 3 shows the relative distribution of patients with combinations of IDH1/2 mutation and MGMT promoter methylation among the 3 cohorts, control, LTS-36, and LTS-60 patients.
IDH1/2-mutant LTS versus IDH1/2-mutant non-LTS
Columns 2 and 4 of Table 3 allow to compare 23 LTS-36 patients with IDH1/2 mutations versus 11 patients with IDH1/2 mutations who survived for less than 36 months. Their median survival was 12 months and thus similar to the median survival of the general non-LTS cohort (Table 1) . Death from tumor progression was confirmed in all 11 patients. None of these tumors had an oligodendroglioma component. The only other remarkable difference between these 2 cohorts of patients with IDH1/2-mutant glioblastoma were the rates of MGMT promoter methylation: there were 17 methylated, 4 weakly methylated, and only 2 unmethylated tumors in IDH1/2-mutant LTS, but 4 methylated, 1 weakly methylated, and 6 unmethylated tumors in the IDH1/2-mutant control patients (P ¼ 0.016).
IDH1/2 wild-type LTS versus IDH1/2 wild-type non-LTS
Columns 3 and 5 of Table 3 allow to compare 44 LTS-36 patients without IDH1/2 mutations versus 229 patients without IDH1/2 mutations who survived for less than 36 months. The major differences between these groups were (expectedly) a higher number of patients who were not treated at all after surgery among control patients and a strong enrichment of patients with MGMT promoter methylation in the LTS group.
Discussion
The clinical and molecular determinants of extended survival in glioblastoma remain uncertain, but are currently being elucidated using various approaches. Using one of the largest patient populations ever reported, this study defines MGMT status, IDH1/2 status, and age as the most important prognostic factors for surviving the diagnosis of primary glioblastoma for at least 36 months (Table 2 ). Most LTS patients showed a classical glioblastoma morphology, although there was an enrichment for glioblastoma with oligodendroglial component in the LTS patients, in particular in the LTS-60 group. This histologic subtype was more common in IDH1/2 mutant tumors (Table 3 ). In contrast, extent of resection was not different between control group and LTS-36 patients (p ¼ 0.541). Moreover, although fewer patients in the LTS-60 group received radiotherapy alone as initial treatment, no such difference was seen between LTS-36 and control patients, and the differences in salvage treatment are unlikely to account for LTS because one might well argue that patients with less aggressive tumors are more likely to be eligible for multiple salvage therapies.
We delineate 2 main cohorts of primary glioblastoma patients with extended survival beyond 36 months, patients with IDH1/2 mutations and patients without IDH1/2 mutations. Furthermore, IDH1/2 wild-type tumors with and without MGMT promoter methylation can be distinguished (Fig. 3) . IDH1/2 mutations have been associated with overall better prognosis across all diffusely infiltrating malignant astrocytic entities (9, 10, 12, 15, 16) and their absence in elderly glioblastoma patients may explain in part why age is a negative prognostic factor in this disease (17) . However, it has never been explored whether tumors with IDH1/2 mutations are enriched in long-term survivors of glioblastomas. Importantly, this study only included patients with primary glioblastoma, that is, there was no evidence of a prior lower-grade lesion in any of these patients. We report a rate of IDH1/2 mutations of 34.3% (23 of 67) in LTS-36 patients which was much higher than in the general population of glioblastoma patients (5-10%). The molecular profile of these LTS-36 patients with IDH1/2-mutant primary glioblastoma was characterized by an increased prevalence of TP53 mutations and the absence of EGFR amplification (Table 3) . Although a less malignant precursor lesion escaped clinical detection in this group of patients, the pattern of molecular alterations in their tumors was typical of secondary glioblastoma (9) . Accordingly, the concept of primary and secondary glioblastoma should probably be replaced by a molecular concept, for example, of IDH1/2-mutant glioblastoma rather than by the absence or presence of a clinically recognized precursor lesion, because future therapeutic decision making is likely to be more commonly based on molecular profiles. The biological consequences of IDH1/2 mutations are currently being elucidated. Mutant IDH1 proteins generate excessive amounts of 2-hydroxyglutarate (2HG) from a-ketoglutarate (18) . 2HG is a competitive inhibitor of various a-ketoglutarate-dependent dioxygenases (19) . Accordingly, increased 2HG levels are predicted to inhibit histone demethylases and TET hydroxylases, thereby preventing histone demethylation and increasing promoter methylation of multiple genes (19, 20) , including MGMT promoter methylation, and explaining why IDH1/2-mutant gliomas commonly exhibit the glioma-CpG island methylator phenotype (G-CIMP; 21, 22) .
Both LTS cohorts, patients with and without IDH1/2 mutations, share an increased prevalence of MGMT promoter methylation. All patients received alkylating agent chemotherapy at least once in the course of disease. Accordingly, it is impossible to dissect a prognostic versus predictive impact of MGMT promoter methylation in this cohort. Because most IDH1/2-mutant tumors exhibit MGMT promoter methylation, an independent association of MGMT promoter methylation with outcome cannot be assessed in this cohort. The frequent MGMT promoter methylation in IDH1/2 mutant glioblastomas suggests that MGMT belongs to the G-CIMP gene set (23) . This association may explain why MGMT promoter methylation in patients with anaplastic gliomas, tumors with a high frequency of IDH1/2 mutations, confers a prognostic benefit independent of the therapy regime (24, 25) . In contrast, MGMT promoter methylation retained an (almost significant) prognostic significance in patients with IDH1/2 wild-type glioblastoma. The molecular mechanisms inducing MGMT promoter methylation in glioblastomas of such patients remain to be identified. The speculation that these tumors carry alterations in other genes involved in the same pathway as IDH1/ 2 has not been substantiated so far and is unlikely, given their differential genomic and epigenomic profiles. We confirm a lower rate of EGFR amplification in the LTS-36 cohort (26) , but this can now be linked to its virtual absence in patients with IDH1/2-mutant tumors. Interestingly, the EGFR amplification rate in IDH1/2 wild-type tumors was similar in LTS-36 patients (43.2%) and in the control cohort (45.5%). Somewhat surprisingly, among the LTS-36 patients, patients with TP53 mutant tumors had an inferior outcome. This observation corresponds to a similar observation at long-term follow-up in low-grade astrocytoma patients (27) and was more prominent in the IDH1/ 2-mutant LTS-36 patients. Altogether, the determinants of long-term survival in patients with IDH1/2 wild-type glioblastomas, which exhibit the typical molecular phenotype of glioblastomas, beyond MGMT promoter methylation remain to be identified, and even the absence of both IDH1/2 mutations and MGMT promoter methylation does not preclude long-term survival. Finally, except of the report of a small, 9 patient series in 2006 (28) , this study represents the only characterization of a primary glioblastoma cohort surviving for 5 years or more, and molecular data on such patients have never been reported before. Given limitations of tissue availability, we were unable to explore whether the LTS phenotype in our cohort is linked to recently characterized gene expression or DNA methylation signatures (29) (30) (31) . The first high-throughput approaches have indeed suggested links between LTS and decreased retinoic acid signaling (32), enhanced immunerelated gene expression (33) , or distinct DNA methylation profiles (34) , but more studies with larger patient populations seem to be required to decide whether tumor rather than host factors are chiefly responsible for LTS. 
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